1
|
YANG LIU, NAKATA YUKIHIKO. NOTE ON THE UNIQUENESS OF AN ENDEMIC EQUILIBRIUM OF AN EPIDEMIC MODEL WITH BOOSTING OF IMMUNITY. J BIOL SYST 2021. [DOI: 10.1142/s0218339021400076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
For some diseases, it is recognized that immunity acquired by natural infection and vaccination subsequently wanes. As such, immunity provides temporal protection to recovered individuals from an infection. An immune period is extended owing to boosting of immunity by asymptomatic re-exposure to an infection. An individual’s immune status plays an important role in the spread of infectious diseases at the population level. We study an age-dependent epidemic model formulated as a nonlinear version of the Aron epidemic model, which incorporates boosting of immunity by a system of delay equations and study the existence of an endemic equilibrium to observe whether boosting of immunity changes the qualitative property of the existence of the equilibrium. We establish a sufficient condition related to the strength of disease transmission from subclinical and clinical infective populations, for the unique existence of an endemic equilibrium.
Collapse
Affiliation(s)
- LIU YANG
- School of Mathematics and Statistics, Northeast Normal University, 5268 Renmin Street, Changchun, Jilin 130024, P. R. China
| | - YUKIHIKO NAKATA
- Department of Physics and Mathematics, Aoyama Gakuin University, 5-10-1 Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-5258, Japan
| |
Collapse
|
2
|
Bloes DA, Kretschmer D, Peschel A. Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors. Nat Rev Microbiol 2014; 13:95-104. [PMID: 25534805 DOI: 10.1038/nrmicro3390] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The innate immune system recognizes conserved microorganism-associated molecular patterns (MAMPs), some of which are sensed by G protein-coupled receptors (GPCRs), and this leads to chemotactic leukocyte influx. Recent studies have indicated that these processes are crucial for host defence and rely on a larger set of chemotactic MAMPs and corresponding GPCRs than was previously thought. Agonists, such as bacterial formyl peptides, enterococcal pheromone peptides, staphylococcal peptide toxins, bacterial fermentation products and the Helicobacter pylori peptide HP(2-20), stimulate specific GPCRs. The importance of leukocyte chemotaxis in host defence is highlighted by the fact that some bacterial pathogens produce chemotaxis inhibitors. How the various chemoattractants, receptors and antagonists shape antibacterial host defence represents an important topic for future research.
Collapse
Affiliation(s)
- Dominik Alexander Bloes
- Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen 72076, Germany
| | - Dorothee Kretschmer
- Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen 72076, Germany
| | - Andreas Peschel
- Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen 72076, Germany
| |
Collapse
|
3
|
Seroepidemiology of Bordetella pertussis Infection in Fresh College Students in Iran: A Multicenter Study. ARCHIVES OF CLINICAL INFECTIOUS DISEASES 2014. [DOI: 10.5812/archcid.17922] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Rozenbaum MH, De Cao E, Westra TA, Postma MJ. Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around…. Expert Rev Vaccines 2014; 11:1415-28. [DOI: 10.1586/erv.12.130] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
5
|
McGarry LJ, Krishnarajah G, Hill G, Masseria C, Skornicki M, Pruttivarasin N, Arondekar B, Roiz J, Pelton SI, Weinstein MC. Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PLoS One 2014; 9:e72723. [PMID: 24416118 PMCID: PMC3886978 DOI: 10.1371/journal.pone.0072723] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Accepted: 07/12/2013] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVES In February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged ≥65 years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding on a 2010 recommendation for adults >65 that was limited to those with close contact with infants. We evaluated clinical and economic outcomes of adding Tdap booster of adults aged ≥65 to "baseline" practice [full-strength DTaP administered from 2 months to 4-6 years, and one dose of Tdap at 11-64 years replacing decennial Td booster], using a dynamic model. METHODS We constructed a population-level disease transmission model to evaluate the cost-effectiveness of supplementing baseline practice by vaccinating 10% of eligible adults aged ≥65 with Tdap replacing the decennial Td booster. US population effects, including indirect benefits accrued by unvaccinated persons, were estimated during a 1-year period after disease incidence reached a new steady state, with consequences of deaths and long-term pertussis sequelae projected over remaining lifetimes. Model outputs include: cases by severity, encephalopathy, deaths, costs (of vaccination and pertussis care) and quality-adjusted life-years (QALYs) associated with each strategy. Results in terms of incremental cost/QALY gained are presented from payer and societal perspectives. Sensitivity analyses vary key parameters within plausible ranges. RESULTS For the US population, the intervention is expected to prevent >97,000 cases (>4,000 severe and >5,000 among infants) of pertussis annually at steady state. Additional vaccination costs are $4.7 million. Net cost savings, including vaccination costs, are $47.7 million (societal perspective) and $44.8 million (payer perspective). From both perspectives, the intervention strategy is dominant (less costly, and more effective by >3,000 QALYs) versus baseline. Results are robust to sensitivity analyses and alternative scenarios. CONCLUSIONS Immunization of eligible adults aged ≥65, consistent with the current ACIP recommendation, is cost saving from both payer and societal perspectives.
Collapse
Affiliation(s)
- Lisa J. McGarry
- OptumInsight, Cambridge, Massachusetts, United States of America
| | | | - Gregory Hill
- OptumInsight, Cambridge, Massachusetts, United States of America
| | - Cristina Masseria
- GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America
| | | | | | - Bhakti Arondekar
- GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America
| | - Julie Roiz
- GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America
| | | | - Milton C. Weinstein
- OptumInsight, Cambridge, Massachusetts, United States of America
- Harvard University, Harvard School of Public Health, Boston, Massachusetts, United States of America
| |
Collapse
|
6
|
McGarry LJ, Krishnarajah G, Hill G, Skornicki M, Pruttivarasin N, Masseria C, Arondekar B, Pelton SI, Weinstein MC. Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One 2013; 8:e67260. [PMID: 24019859 PMCID: PMC3760878 DOI: 10.1371/journal.pone.0067260] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Accepted: 05/20/2013] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES Health benefits and costs of combined reduced-antigen-content tetanus, diphtheria, and pertussis (Tdap) immunization among adults ≥65 years have not been evaluated. In February 2012, the Advisory Committee on Immunization Practices (ACIP) recommended expanding Tdap vaccination (one single dose) to include adults ≥65 years not previously vaccinated with Tdap. Our study estimated the health and economic outcomes of one-time replacement of the decennial tetanus and diphtheria (Td) booster with Tdap in the 10% of individuals aged 65 years assumed eligible each year compared with a baseline scenario of continued Td vaccination. METHODS We constructed a model evaluating the cost-effectiveness of vaccinating a cohort of adults aged 65 with Tdap, by calculating pertussis cases averted due to direct vaccine effects only. Results are presented from societal and payer perspectives for a range of pertussis incidences (25-200 cases per 100,000), due to the uncertainty in estimating true annual incidence. Cases averted were accrued throughout the patient 's lifetime, and a probability tree used to estimate the clinical outcomes and costs (US$ 2010) for each case. Quality-adjusted life-years (QALYs) lost to acute disease were calculated by multiplying cases of mild/moderate/severe pertussis by the associated health-state disutility; QALY losses due to death and long-term sequelae were also considered. Incremental costs and QALYs were summed over the cohort to derive incremental cost-effectiveness ratios. Scenario analyses evaluated the effect of alternative plausible parameter estimates on results. RESULTS At incidence levels of 25, 100, 200 cases/100,000, vaccinating adults aged 65 years costs an additional $336,000, $63,000 and $17,000/QALY gained, respectively. Vaccination has a cost-effectiveness ratio less than $50,000/QALY if pertussis incidence is >116 cases/100,000 from societal and payer perspectives. Results were robust to scenario analyses. CONCLUSIONS Tdap immunization of adults aged 65 years according to current ACIP recommendations is a cost-effective health-care intervention at plausible incidence assumptions.
Collapse
Affiliation(s)
- Lisa J. McGarry
- OptumInsight, Cambridge, Massachusetts, United States of America
| | | | - Gregory Hill
- OptumInsight, Cambridge, Massachusetts, United States of America
| | | | | | - Cristina Masseria
- GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America
| | - Bhakti Arondekar
- GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America
| | | | - Milton C. Weinstein
- OptumInsight, Cambridge, Massachusetts, United States of America
- Harvard University, Harvard School of Public Health, Boston, Massachusetts, United States of America
| |
Collapse
|
7
|
Uribe KB, Etxebarria A, Martín C, Ostolaza H. Calpain-Mediated Processing of Adenylate Cyclase Toxin Generates a Cytosolic Soluble Catalytically Active N-Terminal Domain. PLoS One 2013; 8:e67648. [PMID: 23840759 PMCID: PMC3694075 DOI: 10.1371/journal.pone.0067648] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Accepted: 05/21/2013] [Indexed: 11/17/2022] Open
Abstract
Bordetella pertussis, the whooping cough pathogen, secretes several virulence factors among which adenylate cyclase toxin (ACT) is essential for establishment of the disease in the respiratory tract. ACT weakens host defenses by suppressing important bactericidal activities of the phagocytic cells. Up to now, it was believed that cell intoxication by ACT was a consequence of the accumulation of abnormally high levels of cAMP, generated exclusively beneath the host plasma membrane by the toxin N-terminal catalytic adenylate cyclase (AC) domain, upon its direct translocation across the lipid bilayer. Here we show that host calpain, a calcium-dependent Cys-protease, is activated into the phagocytes by a toxin-triggered calcium rise, resulting in the proteolytic cleavage of the toxin N-terminal domain that releases a catalytically active "soluble AC". The calpain-mediated ACT processing allows trafficking of the "soluble AC" domain into subcellular organella. At least two strategic advantages arise from this singular toxin cleavage, enhancing the specificity of action, and simultaneously preventing an indiscriminate activation of cAMP effectors throughout the cell. The present study provides novel insights into the toxin mechanism of action, as the calpain-mediated toxin processing would confer ACT the capacity for a space- and time-coordinated production of different cAMP "pools", which would play different roles in the cell pathophysiology.
Collapse
Affiliation(s)
- Kepa B Uribe
- Unidad de Biofísica (CSIC, UPV/EHU) and Departamento de Bioquímica, Universidad del País Vasco UPV/EHU, Bilbao, Spain
| | | | | | | |
Collapse
|
8
|
Fernandez RC. Airborne Transmission of Bordetella pertussis Demonstrated in a Baboon Model of Whooping Cough. J Infect Dis 2012; 206:808-10. [DOI: 10.1093/infdis/jis444] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
|
9
|
Towards selective inhibitors of adenylyl cyclase toxin from Bordetella pertussis. Trends Microbiol 2012; 20:343-51. [PMID: 22578665 DOI: 10.1016/j.tim.2012.04.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2012] [Revised: 03/27/2012] [Accepted: 04/04/2012] [Indexed: 12/19/2022]
Abstract
Whooping cough is a very important medical problem that requires novel approaches for treatment. The disease is caused by Bordetella pertussis, with the calmodulin (CaM)-activated adenylyl cyclase (AC) toxin (also known as CyaA) being a major virulence factor. Hence, CyaA inhibitors could constitute novel therapeutics, but it has been difficult to develop potent drugs with high selectivity over mammalian membranous ACs (mACs). Recent studies have shown that bis-anthraniloyl-substituted nucleoside 5'-triphosphates are potent and selective CyaA inhibitors. In addition, the interaction of CyaA with CaM is very different from the interaction of membranous mAC1 with CaM. Accordingly, compounds that interfere with the CyaA-CaM interaction may constitute a novel class of drugs against whooping cough.
Collapse
|
10
|
Comparative seroepidemiology of pertussis, diphtheria and poliovirus antibodies in Singapore: Waning pertussis immunity in a highly immunized population and the need for adolescent booster doses. Vaccine 2012; 30:3566-71. [DOI: 10.1016/j.vaccine.2012.03.059] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2011] [Revised: 03/16/2012] [Accepted: 03/20/2012] [Indexed: 11/15/2022]
|
11
|
Schuler D, Lübker C, Lushington GH, Tang WJ, Shen Y, Richter M, Seifert R. Interactions of Bordetella pertussis adenylyl cyclase toxin CyaA with calmodulin mutants and calmodulin antagonists: comparison with membranous adenylyl cyclase I. Biochem Pharmacol 2012; 83:839-848. [PMID: 22265637 DOI: 10.1016/j.bcp.2012.01.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 01/03/2012] [Accepted: 01/04/2012] [Indexed: 01/12/2023]
Abstract
The adenylyl cyclase (AC) toxin CyaA from Bordetella pertussis constitutes an important virulence factor for the pathogenesis of whooping cough. CyaA is activated by calmodulin (CaM) and compromises host defense by excessive cAMP production. Hence, pharmacological modulation of the CyaA/CaM interaction could constitute a promising approach to treat whooping cough, provided that interactions of endogenous effector proteins with CaM are not affected. As a first step toward this ambitious goal we examined the interactions of CyaA with wild-type CaM and four CaM mutants in which most methionine residues were replaced by leucine residues and studied the effects of the CaM antagonists calmidazolium, trifluoperazine and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7). CyaA/CaM interaction was monitored by CaM-dependent fluorescence resonance energy transfer (FRET) between tryptophan residues in CyaA and 2'-(N-methylanthraniloyl)-3'-deoxy-adenosine 5'-triphosphate and catalytic activity. Comparison of the concentration/response curves of CaM and CaM mutants for FRET and catalysis revealed differences, suggesting a two-step activation mechanism of CyaA by CaM. Even in the absence of CaM, calmidazolium inhibited catalysis, and it did so according to a biphasic function. Trifluoperazine and W-7 did not inhibit FRET or catalysis. In contrast to CyaA, some CaM mutants were more efficacious than CaM at activating membranous AC isoform 1. The slope of CyaA activation by CaM was much steeper than of AC1 activation. Collectively, the two-step activation mechanism of CyaA by CaM offers opportunities for pharmacological intervention. The failure of classic CaM inhibitors to interfere with CyaA/CaM interactions and the different interactions of CaM mutants with CyaA and AC1 point to unique CyaA/CaM interactions.
Collapse
Affiliation(s)
- Dominik Schuler
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
| | - Carolin Lübker
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
| | - Gerald H Lushington
- Molecular Graphics and Modeling Laboratory, The University of Kansas, KS 66045, USA
| | - Wei-Jen Tang
- Ben May Department of Cancer Research, The University of Chicago, Chicago, IL 60637, USA
| | - Yuequan Shen
- College of Life Sciences, Nankai University, 300071 Tianjin, People's Republic of China
| | - Mark Richter
- Department of Molecular Biosciences, The University of Kansas, Lawrence, KS 66045, USA
| | - Roland Seifert
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
| |
Collapse
|
12
|
Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 2011; 30:544-51. [PMID: 22119924 DOI: 10.1016/j.vaccine.2011.11.065] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2011] [Revised: 11/08/2011] [Accepted: 11/16/2011] [Indexed: 11/29/2022]
Abstract
BACKGROUND Pertussis incidence has been increasing for the past two decades in Norway, as in much of the highly vaccinated world. The greatest increase is in teenagers, although the most severe cases occur in infants. A teenage booster is recommended globally, largely with the aim of reducing infant incidence. However few countries have implemented the booster, and almost no data have been published on its utility in preventing infant cases. We aim to assess the duration of vaccine-induced immunity, and the possibility for a teenage-booster vaccine to protect infants in Norway. METHODS AND FINDINGS We used a unique data set that merged case reports with a national vaccine registry from Norway, 1996-2010, to assess age- and cohort-specific hazards of infection. We also developed and implemented a likelihood-based method for estimating the duration of immunity, taking into account age-contact data relevant for pertussis transmission. The risk of infection in thirteen-year olds increased nearly four-fold, however the hazard in infants did not significantly change. The seasonality of cases in pre-school-aged children differed from that of school-aged children. The introduction of a childhood booster vaccine provided indirect protection for unvaccinated members of the cohort, but little protection to neighboring cohorts. Additionally, we found evidence for increasingly rapid infection after three doses of vaccine, potentially caused by significant and heterogeneous loss of immunity. An estimated 15% of vaccinated individuals lost their immunity within five years after vaccination. CONCLUSIONS Immunity induced by the acellular pertussis vaccine prevents both disease and transmission, but is short-lived and heterogeneous. The age-mixing patterns lead to little contact between teenagers and infants. Therefore, while a teenage booster vaccine campaign would likely provide strong protection for cohorts of teenagers, it would provide little protection for infants.
Collapse
Affiliation(s)
- Jennie S Lavine
- Center for Infectious Disease Dynamics, 501 ASI Bldg, Penn State University, University Park, PA 16802, USA.
| | | | | | | |
Collapse
|